Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Ups Stake In Trivascular Technologies Inc (TRIV)

Deerfield Management, managed by James E. Flynn, has revealed raising its position in Trivascular Technologies Inc (NASDAQ:TRIV). According to a new filing with the Securities and Exchange Commission, Deerfield now owns around 1.70 million shares of the company, up from 632,700 shares the fund disclosed last week. The stake is passive by nature and represents 8.38% of common stock. Deerfield has purchased around1.07 million shares of the company at an average price of $12.00 apiece.


California-based Trivascular Technologies Inc (NASDAQ:TRIV) is a medical device company developing and commercializing innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. The company has a market cap of $259.4 million and its stock trades at $13.30.

Trivascular Technologies Inc (NASDAQ:TRIV) has recently closed its initial public offering of 7.48 million shares of common stock offered at a public offering price of $12.00 per share. The offering ALSO included 975,000 shares sold pursuant to the underwriter’s option to purchase additional shares.

Deerfield is a healthcare focused investment company that specializes in funding R&D, managing hostile takeovers, corporate transitions and financial advisory services, having $3.5 billion in assets. This month, Deerfield reported raising its stake in Insmed Incorporated (NASDAQ:INSM), holding 3.04 million shares of the company. At the beginning of April, the fund disclosed boosting its stake in Streamline Health Solutions Inc. (NASDAQ:STRM) to 1.14 million shares from 325,000 shares reported earlier.

In addition, Deerfield initiated positions in several healthcare companies, including Cara Therapeutics Inc. (NASDAQ:CARA), in which the fund disclosed ownership of 350,000 shares. The fund also increased their stake Alphatec Holdings Inc (NASDAQ:ATEC) to 14.2 million shares. In March, Deerfield reported upping its stake in OvaScience Inc (NASDAQ:OVAS) to 1.8 million shares from 605,600 shares held at the end of the fourth quarter of 2013.

Disclosure: none

Recommended Reading:

Hedge Fund Investor Letters

Whitebox Advisors Cuts Its Stake In Dune Energy Inc (DUNR)

Was Kerrisdale Capital’s Bet on JGWPT Holdings Inc (JGW) a Mistake?

Greenlight Capital 2014 Q1 Investor Letter

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!